Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis
Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis作者机构:Department of Epidemiology and BiostatisticsSchool of Public HealthPeking UniversityBeijing 100191China Department of Mathematics and StatisticsUniversity of Maryland Baltimore CountyBaltimore MD 21250MarylandUSA National Clinical Research Center of Digestive DiseasesBeijing Friendship HospitalCapital Medical UniversityBeijing 100050China The Primary Care UnitSchool of Clinical MedicineUniversity of CambridgeCambridge CB21TNUK Department of Endocrinology and MetabolismPeking University International HospitalBeijing 102206China Department of Clinical Epidemiology and BiostatisticsMcMaster UniversityHamilton L8S 4L8OntarioCanada Department of Endocrinology and MetabolismPeking University People’s HospitalBeijing 100044China
出 版 物:《Biomedical and Environmental Sciences》 (生物医学与环境科学(英文版))
年 卷 期:2020年第33卷第1期
页 面:37-47页
核心收录:
学科分类:1002[医学-临床医学] 100201[医学-内科学(含:心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金:supported by the National Natural Science Foundation of China[No.81302508 71673003 81473067 and 91646107]
主 题:Body mass index Body weight Diabetes mellitus Dipeptidyl-peptidase IV inhibitors Glucagon-like peptide-1 receptor agonists Network meta-analysis Waist circumference
摘 要:Objective To evaluate the effects of incretin-based therapies on body weight as the primary outcome,as well as on body mass index(BMI)and waist circumference(WC)as secondary *** Databases including Medline,Embase,the Cochrane Library,and ***(***)were searched for randomized controlled trials(RCTs).Standard pairwise meta-analysis and network meta-analysis(NMA)were both carried *** risk of bias(ROB)tool recommended by the Cochrane handbook was used to assess the quality of *** analysis,sensitivity analysis,meta-regression,and quality evaluation based on the Grading of Recommendations Assessment,Development,and Evaluation(GRADE)were also *** A total of 292 trials were included in this *** with placebo,dipeptidyl-peptidase IV inhibitors(DPP-4 Is)increased weight slightly by 0.31 kg[95%confidence interval(CI):0.05,0.58]and had negligible effects on BMI and *** with placebo,glucagon-like peptide-1 receptor agonists(GLP-1 RAs)lowered weight,BMI,and WC by-1.34 kg(95%CI:-1.60,-1.09),-1.10 kg/m2(95%CI:-1.42,-0.78),and-1.28 cm(95%CI:-1.69,-0.86),*** GLP-1 RAs were more effective than DPP-4 Is in lowering the three ***,the effects of GLP-1 RAs on weight,BMI,and WC were favorable.